U.S. FDA extends review period for expanded use of Abbvie’s arthritis drug – Reuters
The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc’s rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker said on Wednesday.
